Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3Active not recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Other hematologic neoplasm 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Myeloid 1

Conditions

Glioma 3Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 65Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × ivosidenib × CNS × Clear all
NCT02073994 2026-02-17

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Servier

Phase 1 Completed
174 enrolled
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

NCT03343197 2026-02-17

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Servier

Phase 1 Completed
49 enrolled
CNS

Glioma

NCT04056910 2025-02-27

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

University of Pittsburgh

Phase 2 Completed
15 enrolled 14 charts
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡